Silo Pharma Rallies After Securing Key Patent Allowance

Silo Pharma, Inc. (NASDAQ:SILO) shares are trading higher Tuesday after the company announced that the European Patent Office intends to grant a patent for an application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress.”

• Silo stock is surging to new heights today. Why is SILO stock surging?

Patent Allowance Strengthens IP Portfolio

Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.

The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 (5-HT4) receptor agonists, targeting pathways associated with stress resilience.

CEO Eric Weisblum said the milestone strengthens the company's global intellectual property position and highlights the potential of its 5-HT4 program, which focuses on proactive treatment of stress-related disorders.

The patent, once granted, is expected to provide protection across major European markets. Silo said it is evaluating Unitary Patent protection and key national validations to expand geographic coverage.

The company added that it continues to build a portfolio targeting next-generation central nervous system therapeutics with differentiated mechanisms of action.

Silo Shares Soar Higher

SILO Price Action: At the time of publication, Silo shares are trading 59.02% higher at 56 cents, according to data from Benzinga Pro.

Image via Shutterstock